OncoVista eyes pre-IDE for AdnaTest

OncoVista Innovative Therapies (San Antonio), a biopharmaceutical company specializing in targeted cancer therapies, reported the submission of a request to FDA for a pre-IDE determination meeting for its AdnaGen AdnaTest breast cancer device for the detection of circulating breast tumor cells.

CEO Alexander Weis, PhD, said, "The AdnaTest is intended for use as a prognostic test for women with metastatic breast cancer, in whom the presence of circulating tumor cells is associated with decreased progression-free survival and decreased overall survival and as such can be of tremendous benefit in determining those patients who can best benefit from a certain line of chemotherapy treatment. We look forward to working with the FDA to reach agreement on the design and evaluation criteria for a pivotal study for FDA approval."

Guided Therapeutics ticker symbol GTHP

Guided Therapeutics (GT; Norcross, Georgia) reported being issued stock ticker symbol GTHP. Guided Therapeutics, formerly known as SpectRx, was previously traded under the stock symbol SPRX.

"The company name and stock ticker change reflect the company's focus on developing our non-invasive cancer detection technology," said Mark Faupel, PhD, president/CEO. "We plan to complete the corporate changeover in the coming days with an updated web site."

GT says it is developing a rapid and painless test for the early detection of disease that leads to cervical cancer.